These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 38988097

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Merkel M, Danese D, Chen C, Wang J, Wu A, Yang H, Lin H.
    Expert Opin Pharmacother; 2023; 24(10):1205-1214. PubMed ID: 37219406
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Real life experience of tafamidis for the treatment of Spanish patients with Val30Met transthyretin amyloidosis with polyneuropathy.
    Sanso MAR, Rodriguez AR, Vicente LM, Sevilla T, Garro CB, Martín JF, Vicente AA, de la Prida MM, Dávila LG, Vázquez LG, Valle FM, Pons CC, Bau AF, Barroso EC, López IL, González-Moreno J.
    Med Clin (Barc); 2024 May 17; 162(9):e27-e32. PubMed ID: 38556397
    [Abstract] [Full Text] [Related]

  • 5. Real-world outcomes in non-endemic hereditary transthyretin amyloidosis with polyneuropathy: a 20-year German single-referral centre experience.
    Ungerer MN, Hund E, Purrucker JC, Huber L, Kimmich C, Aus dem Siepen F, Hein S, Kristen AV, Hinderhofer K, Kollmer J, Schönland S, Hegenbart U, Weiler M.
    Amyloid; 2021 Jun 17; 28(2):91-99. PubMed ID: 33283548
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation.
    Schmidt HH, Wixner J, Planté-Bordeneuve V, Muñoz-Beamud F, Lladó L, Gillmore JD, Mazzeo A, Li X, Arum S, Jay PY, Adams D, Patisiran Post-LT Study Group.
    Am J Transplant; 2022 Jun 17; 22(6):1646-1657. PubMed ID: 35213769
    [Abstract] [Full Text] [Related]

  • 8. Long-term treatment of hereditary transthyretin amyloidosis with patisiran: multicentre, real-world experience in Italy.
    Gentile L, Mazzeo A, Briani C, Casagrande S, De Luca M, Fabrizi GM, Gagliardi C, Gemelli C, Forcina F, Grandis M, Guglielmino V, Iabichella G, Leonardi L, Lozza A, Manganelli F, Mussinelli R, My F, Occhipinti G, Fenu S, Russo M, Romano A, Salvalaggio A, Tagliapietra M, Tozza S, Palladini G, Obici L, Luigetti M.
    Neurol Sci; 2024 Sep 17; 45(9):4563-4571. PubMed ID: 38622453
    [Abstract] [Full Text] [Related]

  • 9. Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study.
    Ticau S, Aldinc E, Polydefkis M, Adams D, Coelho T, Ueda M, Hale C, Vest J, Nioi P, Patisiran Global OLE Collaborators.
    Amyloid; 2024 Mar 17; 31(1):1-11. PubMed ID: 37469249
    [Abstract] [Full Text] [Related]

  • 10. Tafamidis: A Review in Transthyretin Amyloidosis with Polyneuropathy.
    Lamb YN, Deeks ED.
    Drugs; 2019 Jun 17; 79(8):863-874. PubMed ID: 31098895
    [Abstract] [Full Text] [Related]

  • 11. Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.
    González-Duarte A, Berk JL, Quan D, Mauermann ML, Schmidt HH, Polydefkis M, Waddington-Cruz M, Ueda M, Conceição IM, Kristen AV, Coelho T, Cauquil CA, Tard C, Merkel M, Aldinc E, Chen J, Sweetser MT, Wang JJ, Adams D.
    J Neurol; 2020 Mar 17; 267(3):703-712. PubMed ID: 31728713
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure-Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis.
    Zhang X, Goel V, Attarwala H, Sweetser MT, Clausen VA, Robbie GJ.
    J Clin Pharmacol; 2020 Jan 17; 60(1):37-49. PubMed ID: 31322739
    [Abstract] [Full Text] [Related]

  • 14. The impact of clinical heterogeneity on conducting network meta-analyses in transthyretin amyloidosis with polyneuropathy.
    Samjoo IA, Salvo EM, Tran D, Amass L, Stewart M, Cameron C.
    Curr Med Res Opin; 2020 May 17; 36(5):799-808. PubMed ID: 32011182
    [Abstract] [Full Text] [Related]

  • 15. Neurofilament Light Chain as a Biomarker of Hereditary Transthyretin-Mediated Amyloidosis.
    Ticau S, Sridharan GV, Tsour S, Cantley WL, Chan A, Gilbert JA, Erbe D, Aldinc E, Reilly MM, Adams D, Polydefkis M, Fitzgerald K, Vaishnaw A, Nioi P.
    Neurology; 2021 Jan 19; 96(3):e412-e422. PubMed ID: 33087494
    [Abstract] [Full Text] [Related]

  • 16. Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.
    Obici L, Berk JL, González-Duarte A, Coelho T, Gillmore J, Schmidt HH, Schilling M, Yamashita T, Labeyrie C, Brannagan TH, Ajroud-Driss S, Gorevic P, Kristen AV, Franklin J, Chen J, Sweetser MT, Wang JJ, Adams D.
    Amyloid; 2020 Sep 19; 27(3):153-162. PubMed ID: 32131641
    [Abstract] [Full Text] [Related]

  • 17. Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial.
    Keohane D, Schwartz J, Gundapaneni B, Stewart M, Amass L.
    Amyloid; 2017 Mar 19; 24(1):30-36. PubMed ID: 28393570
    [Abstract] [Full Text] [Related]

  • 18. Patisiran, an RNAi therapeutic for hereditary transthyretin-mediated amyloidosis: Sub-analysis in Taiwanese patients from the APOLLO study.
    Lin KP, Yang CC, Lee YC, Lee MJ, Vest J, Sweetser MT, White MT, Badri P, Hsieh ST, Chao CC.
    J Formos Med Assoc; 2024 Sep 19; 123(9):975-984. PubMed ID: 38548524
    [Abstract] [Full Text] [Related]

  • 19. Hereditary Transthyretin Amyloidosis and the Impact of Classic and New Treatments on Kidney Function: A Review.
    Meléndrez-Balcázar E, Aranda-Vela K, Cervantes-Hernández A, López-Cureño S.
    Am J Kidney Dis; 2024 Aug 19; 84(2):224-231. PubMed ID: 38484868
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.